MDT

95.54

+0.38%↑

VEEV

283.85

-2.99%↓

A

142.11

+0.46%↑

HQY

91.34

+1.51%↑

TLRY

1.55

+1.31%↑

MDT

95.54

+0.38%↑

VEEV

283.85

-2.99%↓

A

142.11

+0.46%↑

HQY

91.34

+1.51%↑

TLRY

1.55

+1.31%↑

MDT

95.54

+0.38%↑

VEEV

283.85

-2.99%↓

A

142.11

+0.46%↑

HQY

91.34

+1.51%↑

TLRY

1.55

+1.31%↑

MDT

95.54

+0.38%↑

VEEV

283.85

-2.99%↓

A

142.11

+0.46%↑

HQY

91.34

+1.51%↑

TLRY

1.55

+1.31%↑

MDT

95.54

+0.38%↑

VEEV

283.85

-2.99%↓

A

142.11

+0.46%↑

HQY

91.34

+1.51%↑

TLRY

1.55

+1.31%↑

Search

Hutchison China MediTech Ltd ADR

Ouvert

SecteurSoins de santé

15.02 -2.34

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.94

Max

15.39

Chiffres clés

By Trading Economics

Revenu

222M

227M

Ventes

-23M

139M

P/E

Moyenne du Secteur

5.808

36.442

Marge bénéficiaire

163.843

Employés

1,780

EBITDA

6.3M

1.3M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+16.44% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-22M

2.7B

Ouverture précédente

17.36

Clôture précédente

15.02

Sentiment de l'Actualité

By Acuity

50%

50%

170 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 oct. 2025, 21:10 UTC

Principaux Mouvements du Marché

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 oct. 2025, 19:03 UTC

Acquisitions, Fusions, Rachats

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 oct. 2025, 17:58 UTC

Acquisitions, Fusions, Rachats

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 oct. 2025, 17:12 UTC

Résultats

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 oct. 2025, 17:12 UTC

Acquisitions, Fusions, Rachats

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 oct. 2025, 16:59 UTC

Acquisitions, Fusions, Rachats

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 oct. 2025, 23:44 UTC

Market Talk

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 oct. 2025, 23:42 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 oct. 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

16 oct. 2025, 22:15 UTC

Résultats

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 oct. 2025, 22:15 UTC

Résultats

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 oct. 2025, 22:15 UTC

Résultats

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 oct. 2025, 22:02 UTC

Market Talk

Global Equities Roundup: Market Talk

16 oct. 2025, 22:02 UTC

Market Talk

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 oct. 2025, 20:50 UTC

Market Talk
Résultats

Health Care Roundup: Market Talk

16 oct. 2025, 20:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 oct. 2025, 20:23 UTC

Market Talk

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 oct. 2025, 20:20 UTC

Résultats

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 oct. 2025, 20:08 UTC

Acquisitions, Fusions, Rachats

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 oct. 2025, 19:37 UTC

Acquisitions, Fusions, Rachats

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 oct. 2025, 19:26 UTC

Résultats

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 oct. 2025, 19:23 UTC

Market Talk

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 oct. 2025, 19:23 UTC

Résultats

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct. 2025, 18:35 UTC

Market Talk
Résultats

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 oct. 2025, 18:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 oct. 2025, 18:31 UTC

Market Talk

Global Equities Roundup: Market Talk

16 oct. 2025, 18:31 UTC

Market Talk

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 oct. 2025, 16:57 UTC

Market Talk

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Comparaison

Variation de prix

Hutchison China MediTech Ltd ADR prévision

Objectif de Prix

By TipRanks

16.44% hausse

Prévisions sur 12 Mois

Moyen 17.92 USD  16.44%

Haut 25 USD

Bas 13.75 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

3 ratings

1

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

14.24 / 14.78Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

170 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat